COLOPLAST NAM. BDK 1 overview

Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options. For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address:...

2024/25 Interim financial results, Q1 2024/25 1 October 2024 - 31 December 2024 Coloplast delivered 8% organic growth and an EBIT margin 1 of 27% in Q1, in line with expectations. Reported revenue in DKK grew 6% and included negative impact from the divestment of Skin Care and currencies. Organic growth rates by business area: Ostomy Care 7%, Continence Care 7%, Voice and Respiratory Care 11%, Advanced Wound Care 12% and Interventional Urology 1%. Growth in Chronic Care was driven by solid...

T uesday, 4 February 2025 at 11.00 - 12.00am CET (corrected from 10.00 - 11.00am CET in an earlier version of this invitation) In connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference...

Tuesday, 4 February 2025 at 10.00 - 11.00am CET In connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call. The webcast of the conference call will be available during and after the...

Please see enclosed pdf. Attachment 11122024_trading_in_shares_GL...

Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2023/24 was approved. Distribution of year-end dividend of DKK 17.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2023/24 to DKK 22.00 per...

The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area. Revenue from the core Skin Care business amounted to around DKK 400 million in FY 2023/24, with an operating profitability level significantly below the group EBIT margin. Coloplast’s FY 2024/25 financial guidance 1 of organic revenue growth at 8-9% and an EBIT margin before special items of around 28% is unchanged and already includes the...

On 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD) 1 policy regarding skin substitute grafts/cellular and tissue-based products for the treatment of Diabetic Foot Ulcers (DFUs) and venous leg ulcers (VLUs) in the Medicare population. The final LCD policy confirms the introduction of a technical qualification and a clinical efficacy qualification, proposed in a draft LCD policy 2 earlier this year. The final decision also...